Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
> Pharma China Web Edition
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
News
2/4/2026
Chia Tai Tianqing's Anlotinib New Indication Application Rejected
2/4/2026
China Gene‑Editing Startup AccurEdit Raises $75M to Advance Promising...
2/4/2026
WuXi Biologics and Sinorda Join Forces to Develop Bispecific Antibody ...
2/4/2026
Almirall's Seysara Approved in China for Moderate-to-Severe Acne
2/4/2026
Ant Group's AI Health Chatbot Surges in Popularity Amid China's Overbu...
2/4/2026
China's Health Insurance Market Poised for $596B Surge by 2033
2/4/2026
Bayer's Nubeqa Gains Third Approval in China for Advanced Prostate Can...
2/4/2026
CMS Gets Green Light from NMPA to Launch Trials for Novel Kidney Disea...
2/3/2026
NMPA Logs Wave of Novel Drug Approvals and Clinical Trial Clearances L...
2/3/2026
Beijing-Based PrimeGenX Therapeutics' HKSE IPO Application Accepted
2/3/2026
HSG Completes Global Acquisition of Avelox and Launches Anti-Infective...
2/3/2026
New Indication for Novartis' Secukinumab in Non-Radiographic Axial Spo...
2/3/2026
Zonsen PepLib Signs Global Peptide R&D Deal with Eli Lilly
2/3/2026
Siran Bio Advances Global Clinical Development of ALK7 siRNA SA030
2/3/2026
Hengrui's Camrelizumab Combo Accepted by FDA for First-Line Liver Canc...
2/3/2026
Zhiben Wins China IND Approval for AR Molecular Glue Degrader ZB-002 i...
2/3/2026
Newsoara Expands Global Footprint With $135M Deal for vTv's Inflammati...
2/3/2026
China and USFDA Officials Pledge to Deepen Regulatory Cooperation at B...
2/3/2026
China Tightens BMI Fund Oversight for 2026 With Nationwide Crackdown o...
2/3/2026
Zenshine Files for Hong Kong IPO to Fuel Expansion Across Infectious D...
2/3/2026
SanegeneBio Strikes Global RNAi Licensing Deal With Genentech Worth Up...
1/31/2026
Recent Official and Executive Moves
1/31/2026
China's Vaccine Exports Jump More Than 50% in 2025 as Overseas Shipmen...
1/30/2026
China's Basic Medical Insurance Fund Posts Solid Surplus in 2025 as In...
1/30/2026
China Solicits Comments on 103rd Batch of Reference Formulations for C...
1/30/2026
China Releases New Guideline on CMC Changes for Cell Therapy Products
1/30/2026
CDE Issues New Clinical Trial Guideline for Antifibrotic Drugs in Inte...
1/30/2026
CDE Issues Trial Guideline to Standardize Clinical Development of Anti...
1/30/2026
Roche's 2025 Results Highlight Strong China Growth amid Global Expansi...
1/30/2026
CSPC's SYS6055 Becomes First In Vivo CAR-T Therapy Approved for Clinic...
Page:
1
/
60
Total number of articles:
1788
:
[First]
[<<]
[1]
[2]
[3]
[4]
[5]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit